/
Immunology
Angioedema
20
Pipeline Programs↗
23
Active Trials↗
14
Companies Involved↗
Angioedema is an emerging landscape with 20 programs across 14 companies. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical9
Phase 1
No programs
Phase 23
Phase 38
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
13 of 16 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 90% of 20 pipeline programs.
Analysis
Trial Status
113
clinical trials
Completed71 · 63%
Active, not recruiting11 · 10%
Recruiting9 · 8%
Terminated7 · 6%
Withdrawn4 · 4%
Approved for marketing3 · 3%
Other8 · 7%
Clinical Trials
Trial Activity
113 trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release (XR) Tablet for Prophylaxis and Deucrictibant Immediate-release (IR) Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Recruiting·—·Phase 3·NCT07266805·32 enrolled
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Recruiting·—·Phase 4·NCT06818474·5 enrolled
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Active, not recruiting·—·Phase 3·NCT06669754·81 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)